Document Detail


Different uptake of 99mTc-ECD adn 99mTc-HMPAO in the same brains: analysis by statistical parametric mapping.
MedLine Citation:
PMID:  11303889     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to investigate the differences between technetium-99m ethyl cysteinate dimer (99mTc-ECD) and technetium-99m hexamethylpropylene amine oxime (99mTc-HMPAO) uptake in the same brains by means of statistical parametric mapping (SPM) analysis. We examined 20 patients (9 male, 11 female, mean age 62+/-12 years) using 99mTc-ECD and 99mTc-HMPAO single-photon emission tomography (SPET) and magnetic resonance imaging (MRI) of the brain less than 7 days after onset of stroke. MRI showed no cortical infarctions. Infarctions in the pons (6 patients) and medulla (1), ischaemic periventricular white matter lesions (13) and lacunar infarction (7) were found on MRI. Split-dose and sequential SPET techniques were used for 99mTc-ECD and 99mTc-HMPAO brain SPET, without repositioning of the patient. All of the SPET images were spatially transformed to standard space, smoothed and globally normalized. The differences between the 99mTc-ECD and 99mTc-HMPAO SPET images were statistically analysed using statistical parametric mapping (SPM) 96 software. The difference between two groups was considered significant at a threshold of uncorrected P values less than 0.01. Visual analysis showed no hypoperfused areas on either 99mTc-ECD or 99mTc-HMPAO SPET images. SPM analysis revealed significantly different uptake of 99mTc-ECD and 99mTc-HMPAO in the same brains. On the 99mTc-ECD SPET images, relatively higher uptake was observed in the frontal, parietal and occipital lobes, in the left superior temporal lobe and in the superior region of the cerebellum. On the 99mTc-HMPAO SPET images, relatively higher uptake was observed in the medial temporal lobes, thalami, periventricular white matter and brain stem. These differences in uptake of the two tracers in the same brains on SPM analysis suggest that interpretation of cerebral perfusion is possible using SPET with 99mTc-ECD and 99mTc-HMPAO.
Authors:
Y Hyun; J S Lee; J H Rha; I K Lee; C K Ha; D S Lee
Related Documents :
17922669 - Neuropsychiatric lupus: clinical and imaging aspects.
1441899 - Magnetic resonance studies on brain dysfunction induced by organic solvents.
21799599 - Ileosigmoid knot: a case report.
7289699 - Evaluation of the regional blood circulation of the hindbrain by dynamic computed tomog...
16620989 - The use of magnetic resonance imaging (mri) in the study of manganese neurotoxicity.
9140749 - Alterations of lactate (+lipid) concentration in brain tumors with in vivo hydrogen mag...
14968399 - Endoscopic endonasal management of invasive skull base mucocele: report of two cases.
11419149 - Mri of the arthritic small joints: comparison of extremity mri (0.2 t) vs high-field mr...
20056369 - Mr imaging for blunt pancreatic injury.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of nuclear medicine     Volume:  28     ISSN:  0340-6997     ISO Abbreviation:  Eur J Nucl Med     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-04-16     Completed Date:  2001-08-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7606882     Medline TA:  Eur J Nucl Med     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  191-7     Citation Subset:  IM    
Affiliation:
Department of Nuclear Medicine, Inha University College of Medicine, Incheon, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Brain / metabolism*,  radionuclide imaging*
Brain Mapping / methods*
Cysteine / analogs & derivatives,  pharmacokinetics*
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Organotechnetium Compounds / pharmacokinetics*
Radiopharmaceuticals / pharmacokinetics*
Stroke / radionuclide imaging
Technetium Tc 99m Exametazime / pharmacokinetics*
Chemical
Reg. No./Substance:
0/Organotechnetium Compounds; 0/Radiopharmaceuticals; 0/technetium Tc 99m bicisate; 100504-35-6/Technetium Tc 99m Exametazime; 52-90-4/Cysteine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differences in 99mTc-HMPAO brain SPET perfusion imaging between Tourette's syndrome and chronic tic ...
Next Document:  Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and ...